arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Editas Medicine, Inc.

EDIT
$2.53 ▼ -0.21 (-7.66%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
48 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

Editas Medicine, Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $301.8M
Dividend Yield —
Revenue Growth 232.3% ↗
Op. Margin -156.0%
ROIC -9.5% ↗
FCF / Share $-0.25 ↘
Trailing P/E —
Price / Book 2.4x
FCF Yield —
Debt / Equity 0.46
info Valuation on last close. End-of-day price, Nov 5, 2026.

48-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$11.89M
↑ +232.3% —
Net Income Profit after all expenses
$-24.98M
↑ +67.2% —
Operating Margin Operating profit as % of sales
-156.0%
↓ -397.8% 0th
FCF / Share Free cash flow per share
$-0.25
↓ -5.2% —
Long-Term Debt Long-term obligations
$48.24M
↑ +2.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
0
Financial Health ↑
17
Cash Quality ↑
67

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 13 years · 48 quarters